TNF-308: The Inflammation Amplifier
The TNF gene encodes tumor necrosis factor-alpha | a master regulator of inflammation and immune response, produced by macrophages, T cells, and other immune cells. This -308 G>A variant sits in the promoter region | the DNA sequence that controls how much TNF-alpha gets made of the gene on chromosome 6p21.3, within the major histocompatibility complex. The A allele disrupts transcription factor binding sites and increases TNF-alpha production approximately 2-fold compared to the G allele when immune cells are stimulated.
The Mechanism
This is a regulatory variant that affects gene transcription | how much protein gets made from the gene. The -308 position is 308 base pairs upstream of where the TNF gene starts being copied into RNA. The A allele alters binding sites for nuclear transcription factors, leading to enhanced transcriptional activity in immune cells. When your immune system encounters a threat, carriers of the A allele produce substantially more TNF-alpha than GG carriers, amplifying the inflammatory response.
The Evidence
A meta-analysis of 1,774 controls and 1,147 celiac disease cases found the A allele confers a 2-fold increased risk (OR 2.051)
, with
AA homozygotes showing 6.6-fold increased risk (OR 6.626)
.
The A allele leads to approximately 2-fold higher TNF-alpha transcription upon immune cell stimulation
, and
carriers show significantly higher serum TNF-alpha levels
.
The variant also predicts response to anti-TNF biologic drugs | medications like infliximab and etanercept that block TNF-alpha used to treat rheumatoid arthritis and inflammatory bowel disease.
RA patients carrying the GG genotype are better responders to etanercept, while the AA genotype significantly decreases response
.
The same pattern holds for etanercept—GG shows better response than AA or AG
.
Associations have been reported with multiple autoimmune conditions.
In rheumatoid arthritis patients, A allele carriers show higher risk of cardiovascular events (HR 1.72), particularly in those also carrying the rheumatoid shared epitope
. Studies link the variant to increased risk of vitiligo, preeclampsia in Asian and Caucasian populations, and aggressive periodontitis.
Practical Implications
If you have autoimmune disease, particularly rheumatoid arthritis or inflammatory bowel disease, your -308 genotype may influence how well you respond to anti-TNF biologic medications. GG carriers tend to respond better to anti-TNF drugs like etanercept (Enbrel), while A allele carriers may need alternative mechanisms. If you're an A allele carrier who doesn't respond well to one anti-TNF drug, switching to a different mechanism of action (like IL-6 inhibitors or JAK inhibitors) may be more effective than trying another anti-TNF.
For those with one or two A alleles, the A allele doesn't cause inflammation by itself—it amplifies your body's inflammatory response when triggered. This means known inflammatory triggers may provoke stronger responses in A allele carriers, and autoimmune flares may be more intense.
Interactions
The TNF-308 variant sits within a cluster of related TNF polymorphisms including rs361525 | TNF-238 G>A, another promoter variant and rs1799724 | TNF-857 C>T. These variants are in linkage disequilibrium, meaning they're often inherited together. Compound effects with other inflammatory pathway genes (IL-6, IL-10, IL-1) have been documented, particularly for predicting anti-TNF drug response.
All genotypes
Standard inflammatory response and good anti-TNF drug response
You have two copies of the common G allele. Your cells produce normal amounts of TNF-alpha when your immune system is activated. About 74% of people carry this genotype. If you develop an autoimmune condition requiring anti-TNF biologic therapy, research suggests you're likely to respond well to these medications.
Moderately increased TNF-alpha production and intermediate drug response
You have one copy of the A allele and one G allele. Your immune cells produce moderately elevated levels of TNF-alpha when stimulated—roughly 1.5-2 fold higher than GG carriers. About 24% of people share this genotype. This creates a mildly amplified inflammatory response and may influence your response to anti-TNF medications if you need them for autoimmune disease.
Significantly elevated TNF-alpha production and reduced anti-TNF drug response
You have two copies of the A allele. Your immune cells produce approximately 2-fold higher levels of TNF-alpha when stimulated compared to GG carriers. About 2% of people carry this genotype. This substantially amplifies your inflammatory response and is associated with increased risk of multiple autoimmune conditions. If you require anti-TNF biologic therapy, you're significantly less likely to respond well to these drugs.